Larvol Delta - Imara-Announces-First-Patient-Dosed-in-Ardent-Phase-2b-Clinical-Trial-of-IMR687-in-Sickle-Cell-Disease

IMR-687 - Imara, Inc

https://www.globenewswire.com/news-release/2020/08/13/2078187/0/en/Imara-Announces-First-Patient-Dosed-in-Ardent-Phase-2b-Clinical-Trial-of-IMR-687-in-Sickle-Cell-Disease.html

Aug 13, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next